MedTrace Logo

Imaging Tau Deposition in the Brain of Elderly Subjects

NCT02958670 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2023-11-09

No results posted yet for this study

Summary

Cerebral accumulation of tau and beta-amyloid are major factors of Alzheimer's disease pathology. A novel Positron Emission Tomography (PET) tracer (18-F-AV-1451) now offers the ability to study tau protein deposition in vivo in subjects, in which information on cerebral amyloid deposition has already been gathered. This enables to study effects of tau deposition on neuronal integrity, their relation to effects of beta-amyloid deposition and how this contributes to cognitive impairment or well-being in the elderly.

Conditions

Interventions

OTHER

18F-AV-1451 (Tau-PET tracer)

Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan

Sponsors & Collaborators

  • Avid Radiopharmaceuticals

    collaborator INDUSTRY

  • Swiss Federal Institute of Technology

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Christoph Hock, Prof.Dr. med · Professor for Biological Psychiatry, Institute for Regenerative Medicine, University of Zurich

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2024-12-31
Completion
2029-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958670 on ClinicalTrials.gov